Comparison of Glucose-Lowering Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Shuyan GuXiaoqian HuXuemei ZhenLizheng ShiHui ShaoXueshan SunYuxuan GuMinzhuo HuangHengjin DongPublished in: Journal of clinical medicine (2022)
The results suggested a potential treatment hierarchy for clinicians and patients, with the GLP-1RA add-ons being most preferred based on their favorable efficacy and safety profiles; and provided a unified hierarchy of evidence for conducting country-specific cost-effectiveness analyses.